Abstract
Despite their high degree of identity and even higher homology, the two Kat3 transcriptional coactivators, CBP and p300, have distinct functions, particularly within the Wnt/β-catenin signaling cascade. ICG-001, by directly binding to CBP but not p300, inhibits CBP/β-catenin transcription and has served as an invaluable chemical genomic tool to dissect the Wnt signaling cascade and the divergent roles of these two coactivators. However, to date no direct antagonist of the p300/β-catenin interaction has been reported. We now report the identification and validation of the first highly specific, direct p300/β-catenin antagonists, YH249/250 and their ability to maintain pluripotency in ESC.
Keywords: p300, CBP, Wnt signaling, peptide mimetics, stem cell, pluripotency.
Current Molecular Pharmacology
Title:Specific Direct Small Molecule p300/β-Catenin Antagonists Maintain Stem Cell Potency
Volume: 9
Author(s): Yusuke Higuchi, Cu Nguyen, Shin-Ya Yasuda, Michael McMillan, Kouichi Hasegawa and Michael Kahn
Affiliation:
Keywords: p300, CBP, Wnt signaling, peptide mimetics, stem cell, pluripotency.
Abstract: Despite their high degree of identity and even higher homology, the two Kat3 transcriptional coactivators, CBP and p300, have distinct functions, particularly within the Wnt/β-catenin signaling cascade. ICG-001, by directly binding to CBP but not p300, inhibits CBP/β-catenin transcription and has served as an invaluable chemical genomic tool to dissect the Wnt signaling cascade and the divergent roles of these two coactivators. However, to date no direct antagonist of the p300/β-catenin interaction has been reported. We now report the identification and validation of the first highly specific, direct p300/β-catenin antagonists, YH249/250 and their ability to maintain pluripotency in ESC.
Export Options
About this article
Cite this article as:
Higuchi Yusuke, Nguyen Cu, Yasuda Shin-Ya, McMillan Michael, Hasegawa Kouichi and Kahn Michael, Specific Direct Small Molecule p300/β-Catenin Antagonists Maintain Stem Cell Potency, Current Molecular Pharmacology 2016; 9 (3) . https://dx.doi.org/10.2174/1874467208666150526155146
DOI https://dx.doi.org/10.2174/1874467208666150526155146 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Development of Biomarkers in Tumors of Digestive System Part II)
Anti-Cancer Agents in Medicinal Chemistry The Urokinase Receptor Interactome
Current Pharmaceutical Design Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
Current Medicinal Chemistry Polymorphisms of Human N-Acetyltransferases and Cancer Risk
Current Drug Metabolism Genetic Mechanisms and Aberrant Gene Expression during the Development of Gastric Intestinal Metaplasia and Adenocarcinoma
Current Genomics Natural Cyclic Peptides as Clinical and Future Therapeutics
Current Organic Chemistry Development on PEG-modified Poly (Amino Acid) Copolymeric Micelles for Delivery of Anticancer Drug
Anti-Cancer Agents in Medicinal Chemistry Advanced Neoplastic Disease as Immunologic, Endocrine and Metabolic Disorder
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Epidermal Growth Factor Receptor (EGFR) Targeted Therapies in Non- Small Cell Lung Cancer (NSCLC)
Reviews on Recent Clinical Trials Tumor Angiogenesis and VEGFR-2: Mechanism, Pathways and Current Biological Therapeutic Interventions
Current Drug Metabolism Selenium Compounds and Apoptotic Modulation: A New Perspective in Cancer Therapy
Mini-Reviews in Medicinal Chemistry Current Status and Perspectives Regarding the Therapeutic Potential of Targeting EGFR Pathway by Curcumin in Lung Cancer
Current Pharmaceutical Design Promising Chemoprevention of Colonic Aberrant Crypt Foci by <i>Portunus segnis</i> Muscle and Shell Extracts in Azoxymethane-Induced Colorectal Cancer in Rats
Anti-Cancer Agents in Medicinal Chemistry Preclinical Molecular Imaging of the Translocator Protein (TSPO) in a Metastases Model Based on Breast Cancer Xenografts Propagated in the Murine Brain
Current Molecular Medicine Current and Emerging Systemic Therapy in Gastro-Esophageal Cancer “The Old and New Therapy for Metastatic Disease, The Role of Adjuvant and Neoadjuvant Therapy for Localized Disease”
Current Clinical Pharmacology Monitoring T Cell Responses to Cancer Immunotherapy: Can We Now Identify Biomarkers Predicting Patients Who will be Responders
Current Cancer Therapy Reviews Carbon Nanotubes in the Diagnosis and Treatment of Malignant Melanoma
Anti-Cancer Agents in Medicinal Chemistry Targeting of Adhesion Molecules as a Therapeutic Strategy in Multiple Myeloma
Current Cancer Drug Targets The Emergence of Non-coding RNAs as Versatile and Efficient Therapeutic Tools
Current Gene Therapy Let-7a Could Serve as A Biomarker for Chemo-Responsiveness to Docetaxel in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry